Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an ...
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
The compounded GLP-1s that Noom and Hims & Hers are selling are roughly a fifth of the monthly cost of a drug like Ozempic.
In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.
Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.
Since being deemed a public health emergency in 2017, opioids are responsible for 72% of drug overdose deaths in the United ...
Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.